Romidepsin belongs to a class of medications called histone deacetylase inhibitors and is currently approved for treatment of cutaneous and peripheral T-cell lymphomas. Romidepsin was previously investigated for the treatment of chronic lymphocytic leukemia (CLL), and demonstrated potential benefit, but interest in its use declined following phase I clinical trials that showed poor tolerance of a significant side effect profile. We presented a patient with a history of stage II CLL, referred to dermatology for treatment of new-onset of mycosis fungoides (MF), who was treated with romidepsin over seven months. The patient achieved a partial response with 50% decrease in body surface area occupied by MF, thinning of remaining plaques, and nea...
Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). H...
Romidepsin is a cyclic molecule that inhibits histone deacetylases. It is Food and Drug Administrati...
BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell ...
Clinical trial results indicate that romidepsin, a histone deacetylase inhibitor, is a promising tre...
Clinical trial results indicate that romidepsin, a histone deacetylase inhibitor, is a promising tre...
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class of agents ...
Background: Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and...
BACKGROUND: Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and...
AbstractBackgroundTumor stage and folliculotropic mycosis fungoides are uncommon subtypes of cutaneo...
Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or periphera...
BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell ...
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. A...
BACKGROUND: Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetyl...
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typic...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). H...
Romidepsin is a cyclic molecule that inhibits histone deacetylases. It is Food and Drug Administrati...
BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell ...
Clinical trial results indicate that romidepsin, a histone deacetylase inhibitor, is a promising tre...
Clinical trial results indicate that romidepsin, a histone deacetylase inhibitor, is a promising tre...
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class of agents ...
Background: Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and...
BACKGROUND: Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and...
AbstractBackgroundTumor stage and folliculotropic mycosis fungoides are uncommon subtypes of cutaneo...
Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or periphera...
BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell ...
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. A...
BACKGROUND: Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetyl...
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typic...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). H...
Romidepsin is a cyclic molecule that inhibits histone deacetylases. It is Food and Drug Administrati...
BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell ...